Every 8-K that Abvc Biopharma Inc (ABVC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ABVC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABVC filings page.
ABVC BIOPHARMA, INC. (symbol: ABVC) is the issuer of record for a Form 8-K filing submitted to the SEC.
ABVC BioPharma, Inc. postponed the previously announced distribution of ordinary shares of BioKey (Cayman), Inc. that had been scheduled for August 3, 2026. The company now expects the distribution to occur on August 21, 2026, after completing additional administrative, regulatory and tax-related steps.
The record date remains July 24, 2026, and shareholders of ABVC common stock as of that date are expected to receive 0.169464 ordinary shares of BioKey for each ABVC share. The earlier ex-dividend date will be replaced, and a new ex-dividend date will be announced once finalized.
ABVC BioPharma, Inc. has postponed the previously announced distribution of ordinary shares of BioKey (Cayman), Inc., which had been scheduled to occur on August 3, 2026. The decision on August 3, 2026 allows additional time to complete administrative, regulatory, and tax-related requirements needed to carry out the distribution.
The record date for the distribution remains unchanged, and the distribution ratio is unchanged at 0.169464 BioKey ordinary shares for each share of ABVC common stock held as of that record date. The prior ex-dividend date will no longer apply and will be reset when a new distribution date is established. ABVC is working with Nasdaq, The Depository Trust Company, and its transfer agent and plans to announce the revised distribution and ex-dividend dates once finalized.
ABVC BioPharma, Inc. reported a change in its independent auditor. On June 30, 2026, the audit committee dismissed Simon & Edward, LLP and engaged Kreit & Chiu CPA LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Simon & Edward’s audit reports for the years ended December 31, 2024 and 2025 contained no adverse or disclaimed opinions and were not qualified, other than explanatory paragraphs highlighting substantial doubt about ABVC’s ability to continue as a going concern. The company states there were no disagreements with Simon & Edward and no reportable events other than previously disclosed material weaknesses in internal control over financial reporting. ABVC has asked Simon & Edward to provide a confirming letter to the SEC, which is included as an exhibit.
ABVC BioPharma, Inc. reported results from its 2026 annual shareholder meeting held on March 26, 2026. A quorum was present, with 10,612,493 common shares representing 41.74% of the voting power entitled to vote.
Shareholders re-elected all director nominees, each receiving over ten million votes in favor. They also approved the reappointment of Simon & Edward, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 10,597,352 votes for, 12,291 against, and 2,850 abstentions.
In addition, shareholders approved the Plan Proposal, with 9,964,400 votes for, 643,419 against, and 4,674 abstentions, indicating broad support among those present for the company’s equity or incentive plan changes.
ABVC BioPharma, Inc. reported that its previously issued financial statements for the quarter ended September 30, 2025 should no longer be relied upon because of errors in revenue recognition and fair value measurement. The company reversed an aggregate $795,950 of licensing revenue from OncoX and ForSeeCon after determining much of the cash effectively came from related party BioFirst or did not meet contractual payment conditions, and reclassified those amounts to balances with BioFirst and OncoX.
ABVC also remeasured land acquired from director Shuling Jiang, concluding that the fair value of the equity and warrants issued provides a clearer measure than the prior appraisal-based value. This increased the recorded land cost by $798,486 to $4,656,461. The company identified a material weakness in internal control over financial reporting and plans to amend the affected Form 10-Q. Separately, ABVC’s 2025 Form 10-K shows total assets rising 179% to $21.06 million, driven mainly by strategic land and development-oriented assets in Asia.
ABVC BioPharma reports additional unregistered equity sales following a prior offshore offering. Between April 11 and May 27, 2025, the company sold 1,987,557 common shares to 43 Non-U.S. Persons under Regulation S, raising aggregate gross proceeds of about $1,289,750.
Between May 26, 2025, and January 6, 2026, ABVC accepted further subscriptions totaling $2,275,468 on the same terms, issuing 1,500,250 additional common shares at prices between $1.00 and $1.95 per share. These new shares equal about 5.92% of the company’s outstanding common stock as of this filing. Investors entered stock purchase agreements and Voting Rights Proxy Agreements transferring their voting rights to chairman Eugene Jiang. The securities were sold privately to accredited, Non-U.S. investors, are unregistered, and are subject to resale restrictions under U.S. securities laws.
ABVC BioPharma furnished an 8-K to announce its financial results for the third quarter ended September 30, 2025. The company reported these results via a press release attached as Exhibit 99.1.
The disclosure under Item 2.02 is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. The filing also includes Exhibit 104, the cover page interactive data file formatted in Inline XBRL. The notice states it is not an offer to sell or solicit purchases of securities.
ABVC BioPharma (ABVC) approved a performance incentive plan for directors, officers, and select employees. The plan will only take effect after the company achieves a $1B market cap for 30 consecutive trading days on or before December 31, 2027, of which there is no guarantee.
If implemented, awards will equal 1% of the company’s common stock outstanding on the implementation date, sourced from the Amended and Restated 2016 Equity Incentive Plan. The plan is capped at $10 million in total awards, with a $1 million cap per recipient. Grants will be tied to defined milestones and require allocation by the Compensation Committee, endorsement by a majority of independent directors, and final approval by the full Board. The structure is intended to align leadership incentives with shareholder value creation.
ABVC BioPharma, Inc. filed an amended current report to update information about its former independent auditor. The company previously disclosed that WWC, P.C., its independent registered public accounting firm, agreed not to renew its engagement as of October 10, 2024.
In this amendment, ABVC explains that it had provided WWC with the earlier report and asked for a letter to the SEC stating whether WWC agreed with the company’s description of the circumstances. ABVC now reports that WWC has refused to provide that letter.
ABVC BioPharma, Inc. filed a current report to let investors know it has released its financial results for the second quarter ended June 30, 2025. The company states that these results are presented in a press release dated August 14, 2025, which is included as Exhibit 99.1. This information is being furnished rather than filed, meaning it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other SEC filings unless specifically referenced. The report also clarifies that neither the document nor its exhibits constitute an offer to sell or a solicitation to buy any of ABVC’s securities.